 DURHAM, N.C., Nov. 03, 2020 GLOBE NEWSWIRE -- Precision BioSciences, Inc. Nasdaq: DTIL, a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020. 